1. Home
  2. PBYI vs PTMN Comparison

PBYI vs PTMN Comparison

Compare PBYI & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • PTMN
  • Stock Information
  • Founded
  • PBYI 2010
  • PTMN 2006
  • Country
  • PBYI United States
  • PTMN United States
  • Employees
  • PBYI N/A
  • PTMN N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • PTMN Finance: Consumer Services
  • Sector
  • PBYI Health Care
  • PTMN Finance
  • Exchange
  • PBYI Nasdaq
  • PTMN Nasdaq
  • Market Cap
  • PBYI 153.2M
  • PTMN 156.9M
  • IPO Year
  • PBYI N/A
  • PTMN N/A
  • Fundamental
  • Price
  • PBYI $2.97
  • PTMN $16.42
  • Analyst Decision
  • PBYI Strong Buy
  • PTMN Hold
  • Analyst Count
  • PBYI 1
  • PTMN 3
  • Target Price
  • PBYI $7.00
  • PTMN $19.33
  • AVG Volume (30 Days)
  • PBYI 821.3K
  • PTMN 37.9K
  • Earning Date
  • PBYI 02-27-2025
  • PTMN 03-12-2025
  • Dividend Yield
  • PBYI N/A
  • PTMN 16.81%
  • EPS Growth
  • PBYI 492.79
  • PTMN N/A
  • EPS
  • PBYI 0.47
  • PTMN 0.39
  • Revenue
  • PBYI $243,569,000.00
  • PTMN $65,828,000.00
  • Revenue This Year
  • PBYI N/A
  • PTMN N/A
  • Revenue Next Year
  • PBYI N/A
  • PTMN N/A
  • P/E Ratio
  • PBYI $6.38
  • PTMN $42.56
  • Revenue Growth
  • PBYI 6.30
  • PTMN N/A
  • 52 Week Low
  • PBYI $2.23
  • PTMN $15.94
  • 52 Week High
  • PBYI $7.73
  • PTMN $20.84
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 45.95
  • PTMN 48.10
  • Support Level
  • PBYI $2.92
  • PTMN $16.05
  • Resistance Level
  • PBYI $4.06
  • PTMN $16.38
  • Average True Range (ATR)
  • PBYI 0.27
  • PTMN 0.24
  • MACD
  • PBYI -0.03
  • PTMN 0.04
  • Stochastic Oscillator
  • PBYI 4.39
  • PTMN 84.21

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

Share on Social Networks: